Skip to main content Accessibility help
  • Online publication date: March 2015

Chapter 33 - The urinary bladder, urachal remnants, urethra, renal pelves, and ureters


1. Taylor RA, Wang H, Wilkinson SE, et al. Lineage enforcement by inductive mesenchyme on adult epithelial stem cells across developmental germ layers. Stem Cells 2009; 27: 3032–3042.
2. Baskin L, DiSandro M, Li Y, et al. Mesenchymal–epithelial interactions in bladder smooth muscle development: effects of the local tissue environment. J Urol 2001; 165: 1283–1288.
3. Howlett AR, Hodges GM, Rowlatt C. Epithelial–stromal interactions in the adult bladder: urothelial growth, differentiation, and maturation on culture facsimiles of bladder stroma. Dev Biol 1986; 118: 403–415.
4. Tasian G, Cunha G, Baskin L. Smooth muscle differentiation and patterning in the urinary bladder. Differentiation 2010; 80: 106–117.
5. Brandt WD, Matsui W, Rosenberg JE, et al. Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev 2009; 28: 291–304.
6. Li Y, Liu W, Hayward SW, Cunha GR, Baskin LS. Plasticity of the urothelial phenotype: effects of gastro-intestinal mesenchyme/stroma and implications for urinary tract reconstruction. Differentiation 2000; 66: 126–135.
7. Liu AY, Pascal LE, Vêncio RZ, Vêncio EF. Stromal–epithelial interactions in early neoplasia. Cancer Biomarkers 2010; 9: 141–155.
8. Jo Mauch T, Albertine KH. Urorectal septum malformation sequence: insights into pathogenesis. Anat Rec 2002; 268: 405–410.
9. Okonkwo JE, Crocker KM. Cloacal dysgenesis. Obstet Gynecol 1977; 50: 97–101.
10. Warne S, Chitty LS, Wilcox DT. Prenatal diagnosis of cloacal anomalies. Br J Urol Int 2002; 89: 78–81.
11. Eccles MR, Jacobs GH. The genetics of primary vesico-ureteric reflux. Ann Acad Med Singapore 2000; 29: 337–345.
12. De La Rosette J, Smedts F, Schoots C, Hoek H, Laguna P. Changing patterns of keratin expression could be associated with functional maturation of the developing human bladder. J Urol 2002; 168: 709–717.
13. Cunha GR, Chung LW, Shannon JM, Reese BA. Stromal–epithelial interactions in sex differentiation. Biol Reprod 1980; 22: 19–42.
14. Kurzrock EA, Baskin LS, Cunha GR. Ontogeny of the male urethra: theory of endodermal differentiation. Differentiation 1999; 64: 115–122.
15. Bulmer D. The development of the human vagina. J Anat 1957; 91: 490.
16. Cunha GR. Overview of epithelial–mesenchymal interactions in the bladder. Adv Exp Med Biol 1999; 462: 3–5.
17. Aboseif S, El-Sakka A, Young P, Cunha G. Mesenchymal reprogramming of adult human epithelial differentiation. Differentiation 1999; 65: 113–118.
18. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994; 71: 583–594.
19. Yi ES, Shabaik AS, Lacey DL, et al. Keratinocyte growth factor causes proliferation of urothelium in vivo. J Urol 1995; 154: 1566–1570.
20. Volmar KE, Fritsch MK, Perlman EJ, Hutchins GM. Patterns of congenital lower urinary tract obstructive uropathy: relation to abnormal prostate and bladder development and the prune belly syndrome. Ped Develop Pathol 2001; 4: 467–472.
21. Hoyes AD, Ramus NI, Martin BG, Fine structure of the epithelium of the human fetal bladder. J Anat 1972; 111: 415–425.
22. Oelrich TM. The urethral sphincter muscle in the male. Am J Anat 1980; 158: 229–246.
23. Tacciuoli M, Lotti T, de Matteis A, Laurenti C Development of the smooth muscle of the ureter and vesical trigone: histological investigation in human fetus. Eur Urol 1975; 1: 282–286.
24. Batourina E, Choi C, Paragas N, et al. Distal ureter morphogenesis depends on epithelial cell remodeling mediated by vitamin A and Ret. Nat Genet 2002; 32: 109–115.
25. Begg RC. The urachus: its anatomy, histology and development. J Anat 1930; 64: 170–186.
26. Berman SM, Tolia BM, Laor E, et al. Urachal remnants in adults. Urology 1988; 31: 17–21.
27. Barrett DM, Malek RS, Kelalis PP. Observations on vesical diverticulum in childhood. J Urol 1976; 116: 284.
28. Rabin JM, Hirschfield L, Badlani GH. Type IX Ehlers–Danlos syndrome: bladder diverticula with transitional cell carcinoma. Urology 1991; 38: 563–566.
29. Ismail A, Hamad B, Kaabi A, et al. Congenital bladder diverticula as a cause of bladder outlet obstruction in children. Eur J Pediatr Surg 2011; 21: 345–347.
30. Shukla A. Giant bladder diverticula causing bladder outlet obstruction in children. J Urol 2004; 172: 1977–1979.
31. Kruse A. Diverticulum of the bladder simulating ovarian cyst: pitfalls in the differential diagnosis. JBR-BRT 2011; 94: 300.
32. Berrocal T, Lopez-Pereira P, Arjonilla A, Gutierrez J. Anomalies of the distal ureter, bladder and urethra in children: embryologic, radiologic and pathologic features. Radiographics 2002; 22: 1139–1164.
33. Hansel D, Paner G, Nese N, Amin M. Limited smoothelin expression within the muscularis mucosae: validation in bladder diverticula. Hum Pathol 2011; 42: 1770–1776.
34. Temiz A. An atypical bladder diverticulum presented with recurrent peritonitis: case report. Ulus Travma Acil Cerrahi Derg 2011; 17: 365–367.
35. Melekos M. Vesical diverticula: etiology, diagnosis, tumorigenesis and treatment. Analysis of 74 cases. Urology 1987; 30: 453–457.
36. Grubisic I, Lenicek T, Dzombeta T, et al. Primary osteosarcoma of bladder diverticulum mimicking intradiverticular calculus: a case report. Diagnostic Pathology 2011; 6: 37.
37. Nair KPN. Mucous metaplasia and rupture of a urachal cyst as a rare cause of acute abdomen. Br J Urol 1987; 59: 281–282.
38. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimantal evidence. Urology 2001; 57: 47–55.
39. Denson MA, Griebling TL, Cohen MB, Kreder KJ. Comparison of cystoscopic and histological findings in patients with suspected interstitial cystitis. J Urol 2000; 164: 1908–1911.
40. Hunner GL. A rare type of bladder ulcer in women. Report of cases. Trans South Surg Gynecol Assoc 1914; 27: 247.
41. Johansson SL. Interstitial cystitis. Mod Pathol 1993; 6: 738–742.
42. Baurys W, Lavely HT. Acute interstitial cystitis; a new clinical entity; report of a case. Guthrie Clin Bull 1946; 16: 19–22.
43. Berry SH, Bogart LM, Pham C, et al. Development, validation and testing of an epidemiological case definition of interstitial cystitis/painful bladder syndrome. J Urol 2010; 183: 1848–1852.
44. Peeker R, Fall M. Toward a precise definition of interstitial cystitis: further evidence of differences in classic and nonulcer disease. J Urol 2002; 167: 2470–2472.
45. Bogart LM, Berry SH, Clemens JQ Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol 2007; 177: 456–456.
46. Peters KM, Killinger KA, Mounayer MH, Boura JA. Are ulcerative and nonulcerative interstitial cystitis/painful bladder syndrome 2 distinct diseases? A study of coexisting conditions. Urology 2011; 78: 301–308.
47. Yamada T, Murayama T, Mita H, Akiyama K. Subtypes of bladder mast cells in interstitial cystitis. Int J Urol 2000; 7: 292–297.
48. Nazif O, Reichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology 2007; 69(Suppl 4): 24–33.
49. Graham E, Chai TC. Dysfunction of bladder urothelium and bladder urothelial cells in interstitial cystitis. Curr Urol Rep 2006; 7: 440–446.
50. Filippou AS, Grant GS, Theoharides TC. Increased expression of intercellular adhesion molecule 1 in relation to mast cells in the bladder of interstitial cystitis patients. Int J Immunopathol Pharmacol 1999; 12: 49–53.
51. Rössberger J, Fall M, Gustafsson CK, Peeker R. Does mast cell density predict the outcome after transurethral resection of Hunner’s lesions in patients with type 3C bladder pain syndrome/interstitial cystitis? Scand J Urol Nephrol 2010; 44: 433–437.
52. Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007; 69(Suppl 4): 34–40.
53. Rudick CN, Bryce PJ, Guichelaar LA, Berry RE, Klumpp DJ. Mast cell-derived histamine mediates cystitis pain. PLoS One 2008; 3: e2096.
54. Saban R, Saban MR, Maier J, et al. Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients. Am J Physiol Renal Physiol 2008; 295: F1613–1623.
55. Somji S, Garrett SH, Sens DA, et al. Expression of heat shock protein 27 in adult and fetal bladder and in patients with interstitial cystitis. J Urol Pathol 1998; 9: 1–15.
56. Gamper M, Viereck V, Geissbühler V, et al. Gene expression profile of bladder tissue of patients with ulcerative interstitial cystitis. BMC Genom 2009; 10: 199.
57. Bettex M, Oesch I, Zimmermann A. Granular cystitis in girls. Long-term follow-up. Eur Urol 1988; 15: 235–236.
58. Hansson S, Hanson E, Hjalmas K, et al. Follicular cystitis in girls with untreated asymptomatic or covert bacteriuria. J Urol 1990; 143: 330–332.
59. Schlager TA, LeGallo R, Innes D, Hendley JO, Peters CA. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol 2011; 186: 2359–2364.
60. Zaharopoulos P. Cytologic manifestations of cystitis follicularis in urine specimens. Diagn Cytopathol 2002; 27: 205–209.
61. Itano NMB, Malek RS. Eosinophilic cystitis in adults. J Urol 2001; 165: 805–807.
62. Johansson SL, Smout MS, Taylor RJ. Eosinophilic cystitis associated with symptomatic ureteral involvement: a report of two cases. J Urol Pathol 1993; 1: 69–77.
63. Hellstrom HR, Davis BK, Shonnard JW. Eosinophilic cystitis. A study of 16 cases. Am J Clin Pathol 1979; 72: 777–784.
64. Giuliani A, Galati G, Demoro M, et al. Endoluminal metastasis of colon cancer to the urinary bladder via the ureter: report of a case. Surg Today 2010; 40: 1093–1096.
65. Caso J, Qin D, Sexton WJ. Eosinophilic cystitis following immediate post-resection intrasvesical instillation of mitomycin-C. Can J Urol 2010; 17: 5223–5225.
66. Clark T, Chang SS, Cookson MS. Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. J Urol 2002; 167: 1795.
67. Ulker V, Apaydin E, Gursan A, Ozyurt C, Kandiloglu G. Eosinophilic cystitis induced by mitomycin-C. Int Urol Nephrol 1996; 28: 755–759.
68. McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol 2003; 16: 623–629.
69. van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198: 245–251.
70. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63: 8108–8112.
71. Ekelund P, Johansson SL. Polypoid cystitis: a catheter associated lesion of the human bladder. Acta Pathol Microbiol Immunol Scand A 1979; 87A: 179–184.
72. Lane Z, Epstein JI. Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. Am J Surg Pathol 2008; 32: 758–764.
73. Goble NM, Clarke T, Hammonds JC. Histological changes in the urinary bladder secondary to urethral catheterisation. Br J Urol 1989; 63: 354–357.
74. Young RH. Papillary and polypoid cystitis. A report of eight cases. Am J Surg Pathol 1988; 12: 542–546.
75. Swierczynski SL, Epstein JI. Prognostic significance of atypical papillary urothelial hyperplasia. Hum Pathol 2002; 33: 512–517.
76. Buck EG. Polypoid cystitis mimicking transitional cell carcinoma. J Urol 1984; 131: 963.
77. Kim SH, Yang DM, Kim NR. Polypoid and papillary cystitis mimicking a large transitional carcinoma in a patient without a history of catheterization: computed tomography and magnetic resonance findings. J Comput Assist Tomogr 2004; 28: 485–487.
78. Huppman A, Pawel B. Polyps and masses of the pediatric urinary bladder: a 21-year pathology review. Pediatr Dev Pathol 2011; 14: 438–444.
79. Tsuzuki T, Epstein JI. Fibroepithelial polyp of the lower urinary tract in adults. Am J Surg Pathol 2005; 29: 460–466.
80. Al-Ahmadie H, Gomez AM, Trane N, Bove KE. Giant botryoid fibroepithelial polyp of bladder with myofibroblastic stroma and cystitis cystica et glandularis. Pediatr Dev Pathol 2003; 6: 179–181.
81. Del Mistro A, Braunstein JD, Halwer M, Koss LG. Identification of human papillomavirus types in male urethral condylomata acuminata by in situ hybridization. Hum Pathol 1987; 18: 936–940.
82. Melchers WJ, Schift R, Stolz E, Lindeman J, Quint WG. Human papillomavirus detection in urine samples from male patients by the polymerase chain reaction. J Clin Microbiol 1989; 27: 1711–1714.
83. Melicow MM, Roberts TW. Pathology and natural history of urethral tumors in males: a review of 142 cases. Urology 1978; 11: 83–89.
84. Cheng L, Leibovich BC, Cheville JC, et al. Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. Cancer 2000; 88: 1679–1686.
85. Guo CC, Fine SW, Epstein JI. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases. Am J Surg Pathol 2006; 30: 883–891.
86. Nakazaki N, Zaitsu M, Mikami K, et al. Coincidence of HPV11-positive urethral condyloma acuminatum and HPV-negative multiple bladder papillomas in a female. Case Rep Med 2012; 2012: 602819.
87. Anjum MI, Ahmed M, Shroti N, Azzopardi A, Mufti GR. Benign polyps with prostatic-type epithelium of the urethra and the urinary bladder. Int Urol Nephrol 1997; 29: 313–317.
88. Delladetsima J, Theodorou C, Dapolla Y, Dimopoulos C. Prostatic-type epithelium in urinary bladder. Clinical, histologic, amd immunohistochemical study. Urology 1990; 36: 445–448.
89. Hansen BJ, Christiansen SW, Eldrup J. Prostatic-type polyp in the bladder. A case report. Acta Pathol Microbiol Immunol Scand A 1989; 97: 664–666.
90. Ishikawa J, Yasuno H, Higuchi A, Kamidono S, Okada S. Benign polyp with prostatic-type epithelium of the urinary bladder: a case report. Hinyokika Kiyo 1990; 36: 1463–1465.
91. Chan JK, Chow TC, Tsui MS. Prostatic-type polyps of the lower urinary tract: three histogenic types? Histopathology 1987; 11: 789–801.
92. Remick DG, Kumar NB. Benign polyps with prostatic-type epithelium of the urethra and the urinary bladder. A suggestion of histogenesis based on histologic and immunohistochemical studies. Am J Surg Pathol 1984; 8: 833–839.
93. Nowels K, Kent E, Rinsho K, Oyasu R. Prostate specific antigen and acid phosphatase-reactive cells in cystitis cystica and glandularis. Arch Pathol Lab Med 1988; 112: 734–737.
94. Cheng L, Montironi R, Bostwick DG. Villous adenoma of the urinary tract: a report of 23 cases, including 8 with coexistent adenocarcinoma. Am J Surg Pathol 1999; 23: 764–771.
95. Sung W, Park BD, Lee SE, Chang SG. Villous adenoma of the urinary bladder. Int J Urol 2008; 15: 551–553.
96. Nakamura Y, Orikasa K, Fujishima F, et al. A case of villous adenoma of the urinary bladder with tubulovillous architecture: characterization by immunohistochemical analysis. Pol J Pathol 2011; 62: 179–182.
97. Tamboli P, Ro JY. Villous adenoma of urinary tract: a common tumor in an uncommon location. Adv Anat Pathol 2000; 7: 79–84.
98. Siebel JL, Prasad S, Weiss RE, Banclia E, Epstein JI. Villous adenoma of the urinary tract: a lesion frequently associated with malignancy. Hum Pathol 2002; 33: 236–241.
99. Adegboyega PA, Adesokan A. Tubulovillous adenoma of the urinary bladder. Mod Pathol 1999; 12: 735–738.
100. Channer JL, Williams JL, Henry L. Villous adenoma of the bladder. J Clin Pathol 1993; 46: 450–452.
101. Lin JW, Chen WJ. Villous adenoma of the urinary bladder: a case report. Changgeng Yi Xue Za Zhi 1995; 18: 266–269.
102. Miller DC, Gang DL, Gavris V, et al. Villous adenoma of the urinary bladder: a morphologic or biologic entity? Am J Clin Pathol 1983; 79: 728–731.
103. Morse HD. The etiology and pathology of pyelitis cystica, ureteritis cystica and cystitis cystica. Am J Pathol 1928; 4: 33–50.
104. Mostofi FK, Davis CJ. Epithelial abnormalities of urinary bladder. Prog Clin Biol Res 1984; 162A: 81–93.
105. Young RH. Non-neoplastic disorders of the urinary bladder. In: Bostwick DG, Cheng L, eds. Urologic Surgical Pathology. Elsevier/Mosby; 2008.
106. Dhall D, Al-Ahmadie H, Olgac S. Nested variant of urothelial carcinoma. Arch Pathol Lab Med 2007; 131: 1725–1727.
107. Volmar KE, Chan TY, De Marzo AM, Epstein JI. Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma. Am J Surg Pathol 2003; 27: 1243–1252.
108. Eble JN, Young RH. Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol 1997; 14: 98–108.
109. Leroy X, Leteurtre E, De La Taille A, et al. Microcystic transitional cell carcinoma: a report of 2 cases arising in the renal pelvis. Arch Pathol Lab Med 2002; 126: 859–861.
110. Williamson SR, Lopez-Beltran A, Montironi R, Cheng L. Glandular lesions of the urinary bladder: clinical significance and differential diagnosis. Histopathology 2011; 58: 811–834.
111. Coombs LM, Knowles MA, Milroy E. Her2 (cerbB-2, neu, Mac 117) amplification and expression in transitional cell carcinoma. Urol Res 1989; 17: 345–348.
112. Pantanowitz L, Otis CN. Cystitis glandularis. Diagn Cytopathol 2008; 36: 181–182.
113. Lee SE, Chow NH, Chi YC, et al. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 1994; 14: 1317–1324.
114. Waisman SS, Banko J, Cromie WJ. Single polypoid cystitis cystica and glandularis presenting as benign bladder tumor. Urol Int 1990; 36: 364–366.
115. Caner V, Turk NS, Duzcan F, et al. No strong association between Her-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008; 14: 261–266.
116. Sung MT, Lopez-Beltran A, Eble JN, et al. Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod Pathol 2006; 19: 1395–1401.
117. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 2011; 60: 350–357.
118. Kuncova J, Urban M, Mandys V. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. APMIS 2007; 115: 1194–1205.
119. Jacobs LB, Brooks JD, Epstein JI. Differentiation of colonic metaplasia from adenocarcinoma Hum Pathol 1997; 28: 1152–1157.
120. Young RH, Bostwick DG. Florid cystitis glandularis of intestinal type with mucin extravasation: a mimic of adenocarcinoma. Am J Surg Pathol 1996; 20: 1462–1468.
121. Bullock PS, Thoni DE, Murphy WM. The significance of colonic mucosa (intestinal metaplasia) involving the urinary tract. Cancer 1987; 59: 2086–2090.
122. Heyns CF, Kock ML, Kirsten PH, van Velden DJ. Pelvic lipomatosis associated with cystitis glandularis and adenocarcinoma of the bladder. J Urol 1991; 145: 364–366.
123. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998; 186: 157–164.
124. Bryan RT, Nicholls JH, Harrison RF, Jankowski JA, Wallace DM. The role of beta-catenin signaling in the malignant potential of cystitis glandularis. J Urol 2003; 170: 1892–1896.
125. Batt RE, Smith RA, Buck Louis GM, et al. Mullerianosis. Histol Histopathol 2007; 22: 1161–1166.
126. Islam S, Tumman JJ, McMahon RF, Payne SR. Mullerianosis of the urinary bladder. Br J Urol Int 2003; 92(Suppl 3): e23.
127. Marhgulis V, Lemack GE, Molberg K, Saboorian MH. Bladder “Mullerianosis” in a woman with lower urinary tract symptoms and hematuria. J Urol 2001; 165: 1996–1997.
128. Ogah K, Hartis R, Hilton P. Mullerianosis involving the urinary bladder. Int Urogynecol J Pelvic Floor Dysfunct 2012; 23: 123–125.
129. Sampson JA. Heterotopic or misplaced endometrial tissue. Am J Obstet Gynecol 1925; 10: 649–664.
130. Young RH, Clement PB, Mullerianosis of the urinary bladder. Mod Pathol 1996; 9: 731–737.
131. Trpkov K, Guggisberg K, Yilmaz A. Arias-Stella reaction as a diagnostic pitfall in a bladder biopsy with endometriosis: case report and review of the pseudoneoplastic bladder lesions. Pathol Res Pract 2009; 205: 653–656.
132. Vella O, Nair N, Ferryman SR, et al. Mullerianosis of the urinary bladder. Int J Surg Pathol 2011; 19: 548–551.
133. Guan H, Rosenthal DL, Erozan YS. Mullerianosis of the urinary bladder: report of a case with diagnosis suggested in urine cytology and review of literature. Diagn Cytopathol 2012; 40: 997–1001.
134. Jimenez-Heffernan JA, Sanchez-Piedra D, Bernaldo de Quiros L, Martinez V. Endosalpingiosis (mullerianosis) of the bladder: a potential source of error in urinary cytology. Cytopathology 2000; 11: 348–353.
135. Clement PB, Young RH. Endocervicosis of the urinary bladder. A report of six cases of a benign müllerian lesion that may mimic adenocarcinoma. Am J Surg Pathol 1992; 16: 533–542.
136. Nazeer T, Ro JY, Tornos C, Ordonez NG, Ayala AG. Endocervical type glands in urinary bladder: a clinicopathologic study of six cases. Hum Pathol 1996; 27: 816–820.
137. Young RH. Pseudoneoplastic lesions of the urinary bladder and urethra: a selective review with emphasis on recent information. Semin Diagn Pathol 1997; 14: 133–146.
138. Kudva R, Hegde P. Mullerianosis of the urinary bladder. Ind J Urol 2012; 28: 206–207.
139. Maccagnano C, Pellucchi F, Rocchini L, et al. Diagnosis and treatment of bladder endometriosis: state of the art. Urol Int 2012; 89: 245–258.
140. Schrodt GR, Alcorn MO, Ibanez J. Endometriosis of the male urinary system: a case report. J Urol 1980; 124: 722–723.
141. Pinkert TC, Catlow CE, Straus R. Endometriosis of the urinary bladder in a man with prostatic carcinoma. Cancer 1979; 43: 1562–1567.
142. Zhao H, Wang Q, Bai C, He K, Pan Y. A cross-study gene set enrichment analysis identifies critical pathways in endometriosis. Reprod Biol Endocrinol 2009; 7: 94.
143. Al-Khawaja M, Tan PH, MacLennan GT, et al. Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. Hum Pathol 2008; 39: 954–959.
144. Clement PB. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol 2007; 14: 241–260.
145. Donne C, Vidal M, Buttin X, et al. Mullerianosis of the urinary bladder: clinical and immunohistochemical findings. Histopathology 1998; 33: 290–292.
146. Hao H, Tsujimoto M, Tsubamoto H, Komori S, Hirota S. Immunohistochemical phenotype of the urinary bladder endocervicosos: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix. Pathol Int 2010; 60: 528–532.
147. Koren J, Mensikova J, Mukensnabl P, Zamecnik M. Mullerianosis of the urinary bladder: report of a case with suggested metaplastic origin. Virchows Archiv A 2006; 449: 268–271.
148. Koraitim MM, Metwalli NE, Atta MA, el-Sadr AA. Changing age incidence and pathological types of schistosoma-associated bladder carcinoma. J Urol 1995; 154: 1714–1716.
149. Abdulamir AS, Hafidh RR, Kadhim HS, Abubakar F. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res 2009; 28: 27.
150. El-Meghawry El-Kenawy A, El-Kott AF, Hasan MS. Heat shock protein expression independently predicts survival outcome in schistosomiasis-associated urinary bladder cancer. Int J Biol Markers 2008; 23: 214–218.
151. Levenback C, Eifel PJ, Burke TW, Morris M, Gershenson DM. Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol 1994; 55: 206–210.
152. Pillay PK, Teh M, Chua EJ, et al. Haemorrhagic chronic radiation cystitis – following treatment of pelvic malignancies. Ann Acad Med Singapore 1984; 13: 634–638.
153. Chancellor MB, McGinnis DE, Shenot PJ, Hirsch IH, Kiiholma PJ. Lyme cystitis and neurogenic bladder dysfunction. Lancet 1992; 339: 1237–1238.
154. Eble JN, Banks ER. Post-surgical necrobiotic granulomas of urinary bladder. Urology 1990; 35: 454–457.
155. Friedell GH, Soto EA, Parija GC, Nagy GK. The renal pelvis, ureter, urinary bladder and urethra. In Silverberg SG, ed. Principles and Practice of Surgical Pathology, 2nd edn. New York, NY: Churchill Livingstone; 1983: p. 1125.
156. Hansen BJ, Horby J, Hansen HJ. Wegener’s granulomatosis in the bladder. Br J Urol Int 1990; 65: 108–109.
157. Hofman P, Quintens H, Michiels JF, Taillan B, Thyss A. Toxoplasma cystitis associated with acquired immunodeficiency syndrome. Urology 1993; 42: 589–592.
158. Londergan TA, Walzak MP. Hemorrhagic cystitis due to adenovirus infection following bone marrow transplanation. J Urol 1994; 151: 1013–1014.
159. McClanahan C, Grimes MM, Callahan E, Stewart J. Hemorrhagic cystitis associated with herpes simplex virus. J Urol 1994; 151: 152–153.
160. Thackray AC The urinary passages. In Wright GP, Symmers WS, eds. Systemic Pathology. London: Longman; 1966: pp. 769–800.
161. Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol 2006; 125: 675–681.
162. Kamat AM, Mathew P. Bladder cancer: imperatives for personalized medicine. Oncology (Williston Park) 2011; 25: 951–958.
163. Alexa A, Baderca F, Zahoi DE, et al. Clinical sigbnificance of Her2/neu overexpression in urothelial carcinomas. Rom J Morphol Embryol 2010; 51: 277–282.
164. Tsiriopoulos I, Kiorpelidou D, Gaitanis G, Sofikitis N, Bassukas ID. Lower urinary tract involvement in patients with newly diagnosed autoimmune bullous dermatoses: an urethrocystoscopic study. Am J Med Sci 2010; 340: 109–113.
165. Leung AY, Mak R, Lie AK, et al. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transpl 2002; 29: 509–513.
166. Leung AY, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transpl 2005; 36: 929–937.
167. Monge M, Chauveau D, Cordonnier C, et al. Localized amyloidosis of the genitourinary tract: report of 5 new cases and review of the literature. Medicine (Baltimore) 2011; 90: 212–222.
168. Javed A, Canales BK, MacLennan GT. Bladder amyloidosis. J Urol 2010; 183: 2388–2389.
169. Larrimore C. Chronic familial Mediterranean fever with development of secondary amyloidosis. Clin Lab Sci 2011; 24: 2–7.
170. Andrade MJ. Lower urinary tract dysfunction in familial amyloidotic polyneuropathy, Portuguese type. Neurourol Urodyn 2009; 28: 26–32.
171. Khan S, Birch P, Bass P, Williams JH, Theaker JM. Localized amyloidosis of the lower genitourinary tract: a clinicopathological and immunohistochemical study of nine cases. Histopathology 1992; 21: 143–147.
172. Chan ES, Ng CF, Chui KL, Hou SM, Yip SK. Primary bladder amyloidosis – case report of a patient with delayed upper urinary tract obstruction 3 years after the diagnosis. Amyloid 2010; 17: 36–38.
173. Kinzel RC, Harrison EG, Utz DC. Primary localized amyloidosis of the bladder. J Urol 1961; 85: 785–795.
174. Tirzaman O, Wahner-Roedler DL, Malek RS, et al. Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000; 75: 1264–1268.
175. Biewend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid 2006; 13: 135–142.
176. Caldamone AA, Elbadawi A, Moshtaqi A, Frank IN. Primary localized amyloidosis of urinary bladder. Urology 1980; 15: 174–180.
177. Malek RS, Wahner-Roedler DL, Gertz MA, Kyle R. Primary localized amyloidosis of the bladder: experience with dimethyl sulfoxide therapy. J Urol 2002; 168: 1018–1020.
178. Merrimen JL, Alkhudair WK, Gupta R. Localized amyloidosis of the urinary tract: case series of nine patients. Urology 2006; 67: 904–909.
179. Singh AK, Floyd MS, De Bolla AR. Bladder amyloidosis mimicking carcinoma. Urol J 2011; 8: 97.
180. Patel S, Trivedi A, Dholaria P, et al. Recurrent multifocal primary amyloidosis of urinary bladder. Saudi J Kidney Dis Transpl 2008; 19: 247–249.
181. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583–596.
182. McCammon KA, Lentzner AN, Moriarty RP, Schellhammer PF. Intravesical dimethyl sulfoxide for primary amyloidosis of the bladder. Urology 1998; 52: 1136–1138.
183. Nurmi MJ, Ekfors TO, Rajala PO, Puntala PV. Intravesical dimethyl sulfoxide instillations in the treatment of secondary amyloidosis of the bladder. J Urol 1990; 143: 808–810.
184. Vaidyanathan S, Mansour P, Soni BM, Singh G. Pathology of the Neuropathic Bladder Caused By Spinal Cord Injury. Philadelphia, PA: Saunders; 2004.
185. Delnay KM, Stonehill WH, Goldman H, Jukkola AF, Dmochowski RR. Bladder histological changes associated with chronic indwelling urinary catheter. J Urol 1999; 161: 1106–1108.
186. Mitsui T, Minami K, Furuno T, Morita H, Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol 2000; 38: 434–438.
187. Janzen J, Vuong PN, Bersch U, Michel D, Zaech GA. Bladder tissue biopsies in spinal cord injured patients: histopathologic aspects of 61 cases. Neurourol Urodyn 1998; 17: 525–530.
188. West DA, Cummings JM, Longo WE, et al. Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology 1999; 53: 292–297.
189. Pannek J. Transitional cell carcinoma in patients with spinal cord injury: a high risk malignancy? Urology 2002; 59: 240–244.
190. Subramonian K, Cartwright RA, Harnden P, Harrison SC. Bladder cancer in patients with spinal cord injuries Br J Urol Int 2004; 93: 739–743.
191. Nomikos M, Philippou P, Glava C, Delakas D. Urothelial carcinoma of the sarcomatoid variant in a young patient with spina bifida: a case report and review of the literature. Cases J 2009; 2: 9381.
192. Austin JC, Elliott S, Cooper CS. Patients with spina bifida and bladder cancer: atypical presentation, advanced stage and poor survival. J Urol 2007; 178: 798–801.
193. Stonehill WH, Dmochowski RR, Patterson AL, Cox CE. Risk factors for bladder tumors in spinal cord injury patients. J Urol 1996; 155: 1248–1250.
194. Apostolidis A, Jaques TS, Freeman D, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur J Urol 2008; 53: 1245–1253.
195. Gevaert T, De Vos R, Everaerts W, et al. Characterization of upper lamina propria interstitial cells in bladders from patients with neurogenic detrusor overactivity and bladder pain syndrome. J Cell Molec Med 2011; 15: 2586–2593.
196. Benson RCJ, Swanson SK, Farrow GM. Relationship of leukoplakia to urothelial malignancy. J Urol 1984; 131: 507–511.
197. Widran J, Sanchez R, Gruhn J. Squamous metaplasia of the bladder: a study of 450 patients. J Urol 1974; 112: 479–482.
198. Corica FA, Husmann DA, Churchill BM, et al. Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. Urology 1997; 50: 427–431.
199. Oyama N, Tanase K, Akino H, et al. Nephrogenic adenoma in a patient with transitional cell carcinoma of the bladder receiving intravesical bacillus Calmette–Guerin. Int J Urol 1998; 5: 185–187.
200. Rahemtullah A, Oliva E. Nephrogenic adenoma: an update on an innocuous but troublesome entity. Adv Anat Pathol 2006; 13: 247–255.
201. McIntire TL, Soloway MS, Murphy WM. Nephrogenic adenoma. Urology 1987; 29: 237–241.
202. Oliva E, Young RH. Nephrogenic adenoma of the urinary tract: a review of the microscopic appearance of 80 cases with emphasis on unusual features. Mod Pathol 1995; 8: 722–730.
203. Kunju LP. Nephrogenic adenoma: report of a case and review of morphologic mimics. Arch Pathol Lab Med 2010; 134: 1455–1459.
204. Gilcrease MZ, Delgado R, Vuitch F, Albores-Saavedra J. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. Hum Pathol 1998; 29: 1451–1456.
205. Herawi M, Drew PA, Pan CC, Epstein JI. Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. Hum Pathol 2010; 41: 594–601.
206. Hartmann A, Junker K, Dietmaier W, et al. Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma. Hum Pathol 2006; 37: 117–120.
207. Tong GX, Weeden EM, Hamele-Bena D, et al. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol 2008; 32: 1380–1387.
208. Brimo F, Herawi M, Sharma R, et al. Hepatocyte nuclear factor-1β expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis. Hum Pathol 2011; 42: 1613–1619.
209. Cohen SM, Shirai T, Steinbeck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol 2000; 205: 105–115.
210. Koss LG, Melamed MR, Kelly RE. Further cytologic and histologic studies of bladder lesions in workers exposed to para-aminodiphenyl: progress report. J Natl Cancer Inst 1969; 43: 233–243.
211. Murphy WM, Nagy GK, Rao MK, et al. “Normal” urothelium in patients with bladder cancer: a preliminary report from the National Bladder Cancer Collaborative Group A. Cancer 1979; 44: 1050–1058.
212. Shinka T, Sawada Y, Morimoto S, et al. Clinical study on urothelial tumors of dye workers in Wakayama City. J Urol 1991; 146: 1504–1507.
213. Chaturvedi V, Li L, Hodges S, et al. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene 1997; 14: 2059–2070.
214. Czerniak B, Chaturvedi V, Li L, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999; 18: 1185–1196.
215. Boyd PJ, Burnand KG. Site of bladder-tumour recurrence. Lancet 1974; 2: 1290–1292.
216. Li M, Cannizzaro LA. Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. Hum Pathol 1999; 30: 1197–1200.
217. Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin bladder cancer. N Engl J Med 1992; 326: 737–740.
218. Cheng L, Gu J, Ulbright TM, et al. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer 2002; 94: 104–110.
219. Paiss T, Wohr G, Hautmann RE, et al. Some tumors of the bladder are polyclonal in origin. J Urol 2002; 167: 718–723.
220. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder: can biologic potential be predicted from histologic grading? Cancer 1987; 60: 2766–2774.
221. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. The World Health Organization Classification of Tumours of the Urinary System and Male Genital System. Lyon: IARC Press; 2004: pp. 209–211.
222. Maruniak NA, Takezawa K, Murphy WM. Accurate pathological staging of urothelial neoplasms requires better cystoscopic sampling. J Urol 2002; 167: 2404–2407.
223. Faricy-Anderson KE, Fulton JP, Mega AE. Why does Rhode Island have the greatest incidence of bladder cancer in the United States? Med Health R I 2010; 93: 308, 313–316.
224. Jakszyn P, Gonzalez CA, Lujan-Barroso L, et al. Red meat, dietary nitrosamines, and heme iron and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 2011; 20: 555–559.
225. Zheng YL, Dash C, Loffredo C. Urinary bladder cancer risk factors in Egypt: a multicenter case-control study – Response. Cancer Epidemiol Biomarkers Prev 2012; 21: 694.
226. Czerniak B. Molecular pathology and biomarkers of bladder cancer. Cancer Biomarkers 2011; 9: 159–176.
227. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Ann Rev Pathol 2009; 4: 251–285.
228. Mitra AP, Cote RJ. Molecular screening for bladder cancer: progress and potential. Nat Rev Urol 2010; 7: 11–20.
229. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24: 5552–5564.
230. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 713–725.
231. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol 2003; 170: 1987–1993.
232. Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010; 5: e13821.
233. Lopez-Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006; 66: 7401–7414.
234. Kubota Y, Miyamoto H, Noguchi S, et al. The loss of retinoblastoma gene in association with c-myc and transforming growth factor-beta 1 gene expression in human bladder cancer. J Urol 1995; 154: 371–374.
235. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006; 24: 5552–5564.
236. Owen HC, Giedl J, Wild PJ, et al. Low frequency of epigenetic events in urothelial tumors in young patients. J Urol 2010; 184: 459–463.
237. Dhawan D, Hamdy FC, Rehman I, et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006; 209: 336–343.
238. Han H, Wolff EM, Liang G. Epigenetic alterations in bladder cancer and their potential clinical implications. Adv Urol 2012; 2012: 546917.
239. Knowles MA. Bladder cancer subtypes defined by genomic alterations. Scand J Urol Nephrol Suppl 2008; 218: 116–130.
240.Spruck Chr, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784–788.
241. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23: 675–680.
242. Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 1998; 58: 5348–5353.
243. Kawauchi S, Sakai H, Ikemoto K, et al. 9p21 Index as estimated by dual-color fluorescence in-situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology Hum Pathol 2009; 40: 1783–1789.
244. Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003; 23: 41–48.
245. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169: 2101–2105.
246. Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006; 176: 44–47.
247. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007; 127: 295–301.
248. Ferra S, Denley R, Herr H, et al. Reflex UroVysion testing in suspicious urine cytology cases. Cancer 2009; 117: 7–14.
249. Fritsche HM, Burger M, Dietmaier S, et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol 2010; 134: 597–603.
250. Karnwal A, Venegas R, Shuch B, et al. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer. Can J Urol 2010; 17: 5077–5081.
251. Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2010; 183: 62–67.
252. Maffezzini M, Campodonico F, Capponi G, et al. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res 2010; 30: 4761–4765.
253. Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette–Guerin therapy. Int J Cancer 2009; 124: 2899–2904.
254. Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009 104: 336–339.
255. Birkhahn M, Mitra AP, Williams AJ, et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 2010; 57: 12–20.
256. Cheng L, Zhang S, MacLennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2010; 42: 455–481.
257. Heidenblad M, Lindgren D, Jonson T, et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics 2008; 1: 3.
258. Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010; 70: 3463–3472.
259. Mengual L, Burset M, Ribal MJ, et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res 2010; 16: 2624–2633.
260. Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009; 27: 3929–3937.
261. Miyamoto H, Brimo F, Schultz L, et al. Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med 2010; 134: 1160–1163.
262. Rothman N, Garcia-Closas M, Chatterjee N, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010; 42: 978–984.
263. Sanchez-Carbayo M, Condon-Cardo C Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 2003; 89: 2172–2177.
264. Sanchez-Carbayo M, Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol 2007; 34: 75–84.
265. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002; 62: 6973–6980.
266. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778–789.
267. Serizawa RR, Ralfkiaer U, Steven K, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer 2011; 129: 78–87.
268. O’Donnell MA. Advances in the management of superficial bladder cancer. Semin Oncol 2007; 34: 85–97.
269. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010; 183: 68–75.
270. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414–2422, discussion 2422.
271. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666–675.
272. Romih R, Korosec P, de Mello WJ, Jezernik K. Differentiation of epithelial cells in the urinary tract. Cell Tissue Res 2005; 320: 259–268.
273. Romih R, Veranic P, Jezernik K. Appraisal of differentiation markers in urothelial cells. Appl Immunohistochem Mol Morphol 2002; 10: 339–343.
274. Sanchez Freire V, Burkhard FC, Schmitz A, Kessler TM, Monastyrskaya K. Structural differences between the bladder dome and trigone revealed by mRNA expression analysis of cold-cut biopsies. Br J Urol 2011; 108: E126–135.
275. Riedel I, Liang FX, Deng FM, et al. Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder? Eur J Cell Biol 2005; 84: 393–405.
276. Carder PJ, Murphy CE, Dervan P, et al. A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res Treat 2005; 92: 287–293.
277. Schrohl A-S, Pedersen HC, Jensen SS, Nielsen SL, Brunner N. Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 2011; 59: 975–983.
278. Karni-Schmidt O, Castillo-Martin M, Huai-Shen T, et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011; 178: 1350–1360.
279. Nitz MD, Harding MA, Smith SC, Thomas S, Theodorescu D. RREB1 transcription factor splice variants in urologic cancer. Am J Pathol 2011; 179: 477–486.
280. Tilli TM, Thuler LC, Matos AR, et al. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 2011; 92: 13–19.
281. VuCD45no E, Montesano M, Battista C, et al. Urinary complications from breast cancer metastasis: case report and review of the literature. G Chir 2010; 31: 243–245.
282. Morikawa T, Nishimatsu H, Kadono T, Homma Y, Fukayama M. Urinary bladder metastasis from extramammary Paget’s disease in a patient with a past history of colon and gastric cancers. Pathol Int 2010; 60: 145–146.
283. Nair BC, Williams NC, Cui C, et al. Conjunctival melanoma: bladder and upper urinary tract metastases. J Clin Oncol 2011; 29: e216–219.
284. Hodges KB, Lopez-Beltran A, Emerson RE, Montironi R, Cheng L. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. Appl Immunohistochem Mol Morphol 2010; 18: 401–410.
285. Ud DN, Quereshi A, Mansoor S. Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate. Indian J Pathol Microbiol 2011; 54: 59–62.
286. Coombs LM, Oliver S, Sweeney E, Knowles M. Immunocytochemical localisation of c-erbB-2 protein in transitional cell carcinoma of the urinary bladder. J Pathol 1993; 169: 35–42.
287. Erill N, Colomer A, Verdú M, et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol 2004; 13: 217–223.
288. George B, Datar RH, Wu L, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007; 25: 5352–5358.
289. Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384–1390.
290. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53–59.
291. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in-situ of the bladder. J Urol 1994; 152: 388–392.
292. Garcia del Muro X, Condom E, Vigués F, et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004; 100: 1859–1867.
293. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21, Waf1, p27kipl, cyclin D1 and cyclin D3) and proliferation index (Ki67-MIB1). Eur Urol 2004; 45: 606–612.
294. Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol 2004; 22: 112–118.
295. Shariat SF, Bolenz C, Karakiewicz PI, et al. P53 expression in patients with advanced urothelial cancer of the urinary bladder Br J Urol Int 2010; 105: 489–495.
296. Fu TY, Tu MS, Tseng HH, Wang JS. Overexpression of p27kip1 in urinary bladder urothelial carcinoma. Int J Urol 2007; 14: 1084–1087.
297. Kruger S, Mahnken A, Kausch I, Feller AC. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 2005; 47: 463–467.
298. Lopez-Beltran A, Alvarez-Kindelan J, Luque RJ, et al. Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol 2006; 209: 106–113.
299. Sgambato A, Migaldi M, Faraglia B, et al. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell-cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002; 97: 671–678.
300. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 2007; 25: 468–475.
301. Yin M, Bastacky S, Parwani AV, McHale T, Dhir R. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in-situ. Hum Pathol 2008; 39: 527–535.
302. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007–1013.
303. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007; 177: 481–487
304. Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009; 182: 78–84.
305. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 315–325.
306. Dalbagni G, Presti JJC, Reuter VE, et al. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 1993; 2: 4–13.
307. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217–1221.
308. Chatterjee SJ, George B, Goebell PJ, et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004; 203: 762–770.
309. Benedict WF, Lerner SP, Zhou J, et al. Level of retinoblastoma protein in expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18: 1197–1203.
310. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumour progression. Int J Cancer 1993; 53: 781–784.
311. Cormio L, Tolve I, Annese P, et al. Retinoblastoma protein expression predicts response to bacillus Calmette–Guérin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol 2010; 28: 285–289.
312. Lee K, Jung ES, Choi YJ, Lee KY, Lee A. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma. J Kor Med Sci 2010; 25: 1449–1455.
313. Ahmad I, Morton JP, Singh LB, et al. β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 2011; 30: 178–189.
314. Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration, spreading and focal adhesions by tumour suppresser gene PTEN. Science 1998; 280: 1614–1617.
315. Schechter AL, Stem DF, Vaidyanathan L, et al. The neu oncogene: an erbB related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312: 513–516.
316. Coombs LM, Pigott DA, Sweeney E, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63: 601–608.
317. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650–655.
318. Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 1993; 29: 749–753.
319. Bush C, Price P, Norton J, et al. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br J Cancer 1991; 64: 357–360.
320. Mulder AH, Van Hootegem JC, Sylvester R, et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol 1992; 166: 37–43.
321. Lee AKS, Wiley B, Loda M, et al. DNA ploidy, proliferation and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol 1992; 5: 61–67.
322. Asakura T, Takano Y, Iki M, et al. Prognostic value of Ki-67 for recurrenc and progression of superficial bladder cancer. J Urol 1997; 158: 385–388.
323. Wu TT, Chen J, Lee Y, Huang J. The role of bcl-2, p53 and Ki-67 index in predicting tumour recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163: 758–760.
324. Gontero P, Casetta G, Zitella A, et al. Evaluation of p53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000; 38: 287–296.
325. Margulis V, Lotan Y, Karakiewicz P, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009; 101: 114–119.
326. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006; 12: 7369–7373.
327. Quintero A, Alvarez-Kindelan J, Luque R, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006; 59: 83–88.
328. Ramos D, Ruiz A, Morell L, et al. Prognostic value of morphometry in low grade papillary urothelial bladder neoplasms. Anal Quant Cytol Histol 2004; 26: 285–294.
329. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003; 21: 1912–1921.
330. Vaux D, Cory S, Adams J. Bcl-gene promotes haematopoietic cell survival and co-operates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440–442.
331. Nakopoulou L, Vourlakou C, Zervas A, et al. The prevelance of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998; 29: 146–154.
332. Atug F, Turkeri L, Ozyurek M, Akdas A. Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder. Int Urol Nephrol 1998; 30: 455–461.
333. Kirsch EJ, Baunoch DA, Stadler WM. Expression of bcl-2 and bcl-x in bladder cancer. J Urol 1998; 159: 1348–1353.
334. Li B, Kanamaru H, Noriki S, et al. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urol Res 1998; 26: 235–241.
335. Lipponen P, Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumour malignancy. The Prostate 1997; 32: 9–16.
336. Liukkonen TJ, Lipponen PK, Helle M, et al. Immunoreactivity of bcl-2, p53 and EGFr is associated with tumour stage, grade and cell proliferation in superficial bladder cancer. Finn-bladder III Group. Urol Res 1997; 25: 1–7.
337. Stavropoulos NE, Filiadis I, Ioachim E, et al. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res 2002; 22: 3759–3764.
338. Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Anticancer Res 1998; 18: 4717–4721.
339. Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol 2010; 41: 155–162.
340. Hadaschik BA, Jackson J, Fazli L, et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. Br J Urol Int 2008; 102: 610–616.
341. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53 and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 2003; 16: 187–191.
342. Kunju LP, Lee CT, Montie J, Shah RB. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int 2005; 55: 248–254.
343. Yin H, He Q, Li T, Leong AS. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol 2006; 2006: 260–265.
344. Chan CW, Wong NA, Liu Y, et al. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci USA 2009; 106: 1936–1941.
345. Nakazawa K, Murata S, Yuminamochi T, et al. p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. Am J Clin Pathol 2009; 132: 776–784.
346. Buza N, Cohen PJ, Pei H, Parkash V. Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder. Int J Surg Pathol 2010; 18: 94–102.
347. Li H, Jeong YM, Kim SY, Kim MK, Kim DS. Arbutin inhibits TCCSUP human bladder cancer cell proliferation via up-regulation of p21. Pharm Unserer Zeit 2011; 66: 306–309.
348. de Carne Trecessson T, Guillemin Y, Belanger A, et al. Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins. J Biol Chem 2011; 286: 12835–13838.
349. Oeggerli M, Tomovska S, Schraml P, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004; 23: 5616–5623.
350. Oeggerli M, Schraml P, Ruiz C, et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 2006; 25: 6538–6543.
351. Olsson AY, Feber A, Edwards S, et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007; 26: 1028–1037.
352. Feber A, Clark J, Goodwin G, et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004; 23: 1627–1630.
353. Al-Ahmadie HA, Iyer G, Janakiraman M, et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol 2011; 224: 270–279.
354. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158: 1955–1959.
355. Bolenz C, Shariat S, Karakiewicz P, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. Br J Urol Int 2010; 106: 1216–1222.
356. Eissa S, Ali HS, Al Tonsi AH, Zaglol A, El Ahmady O. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem 2005; 38: 142–148.
357. Gandour-Edwards R, Lara PNJ, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002; 95: 1009–1015.
358. Latif Z, Watters AD, Dunn IB, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for antiHER2 therapy? Eur J Cancer 2004; 40: 56–63.
359. Leibl S, Zigeuner R, Hutterer G, et al. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. Acta Pathol Microbiol Immunol Scand A 2008; 116: 27–32.
360. Ling S, Chang X, Schultz L, et al. An EGFR–ERK–SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res 2011; 71: 3812–3821.
361. Mason RA, Morlock EV, Karagas, ME, et al. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis 2009; 30: 1155–1160.
362. Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005; 95: 1344–1350.
363. Simonetti S, Russo R, Ciancia G, et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009; 17: 198–205.
364. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 2010; 16: 3011–3018.
365. Miyake M, Sugano K, Sugino H, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci 2010; 101: 250–258.
366. van Rhijn B, Zuiverloon T, Vis A, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010; 58: 433–441.
367. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 465–466.
368. Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Bio Ther 2010a; 10: 407–415.
369. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62: 309–317.
370. Jimenez RE, Hussain M, Bianco FJJ, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440–2447.
371. Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 1997; 25: 9–17.
372. Zupancic D, Zakrajsek M, Zhou G, Romih R. Expression and localization of four uroplakins in urothelial preneoplastic lesions. Histochemical Cell Biology 2011; 136: 491–500.
373. Olsburgh J, Harnden P, Weeks R, et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 2003; 199: 41–49.
374. Koga F, Kawakami S, Fujii Y, et al. Impaired p63 expression associates with poor prognosis and uroplakin III carcinoma of the bladder. Clin Cancer Res 2003; 9: 5501–5507.
375. Huang HD, Shariat SF, Sun TT, et al. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor preogression and clinical outcome. Hum Pathol 2007; 38: 1703–1713.
376. Badve S, Logdberg L, Sokhi R, et al. An antigen reacting with das-1 monoclonal antibody is ontogenically regulated in diverse organs including liver and indicates sharing of developmental mechanisms among cell lineages. Pathobiology 2000; 68: 76–86.
377. Rogge-Wolf C, Seldenrijk CA, Das KM, et al. Prevalence of mabDAS-1 positivity in biopsy specimens from the esophagogastric junction. Am J Gastroenterol 2002; 97: 2979–2985.
378. Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol 2001; 25: 1380–1387.
379. Raspollini MR, Nesi G, Baroni G, Girardi LR, Taddei GL. Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder. Appl Immunohistochem Mol Morphol 2005; 13: 356–362.
380. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol 2012; 36: 1472–1476.
381. Broders AC. Epithelium of the genito-urinary organs. Ann Surg 1922; 75: 574–604.
382. Eble J, Sauter G, Epstein J, Sesterhenn I. Tumors of the urinary system and male genital organs. In WHO Classification of Tumors. Pathology and Genetics 2004.
383. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998a; 22: 1435–1448.
384. Malmstrom P-U, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer: a retrospective analysis of 232 patients with >5 year follow-up. Scand J Urol Nephrol 1987; 21: 185–195.
385. Taylor D, Bhagavan B, Larsen M, Cox J, Epstein J. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am J Surg Pathol 1996; 20: 1481–1488.
386. Chow NH, Cairns P, Eisenberger CF, et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000; 89: 514–518.
387. Gonul I, Poyraz A, Unsal C, Acar C, Alkibay T. Comparison of 1998 WHO/ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases. Urol Int 2007; 78: 338–344.
388. Mamoon N, Iqbal MA, Jamal S, Luqman M. Urothelial neoplasia of the urinary bladder – comparison of interobserver variability for WHO Classification 1972 with WHO/ISUP Consensus Classification 1998. J Ayub Med Coll 2006; 18: 4–8.
389. Burger M, Denzinger S, Wieland WF, et al. Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset? BJU Int 2008; 102: 194–197.
390. Pan CC, Chang YH, Chen KK, et al. Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder. J Clin Pathol 2010; 63: 910–915.
391. Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 2010; 133: 788–795.
392. Chaux A, Karram S, Miller JS, et al. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Hum Pathol 2012; 43: 115–120.
393. Lee TK, Chaux A, Karram S, et al. Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center. Hum Pathol 2011; 42: 1799–1803.
394. Cheville JC, Wu K, Sebo TJ, et al. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?. Cancer 2000; 88: 632–636.
395. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435–1448.
396. Cheng L, Darson M, Cheville JC, et al. Urothelial papilloma of the bladder: clinical and biologic implications. Cancer 1999; 86: 2098–2101.
397. Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007; 178: 1201–1205.
398. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002; 60: 315–319.
399. Magi-Galluzzi C, Epstein JI. Urothelial papilloma of the bladder: a review of 34 de novo cases. Am J Surg Pathol 2004; 28: 1615–1620.
400. Fine SW, Chan TY, Epstein JI. Inverted papillomas of the prostatic urethra. Am J Surg Pathol 2006; 30: 975–979.
401. Fine SW, Epstein JI. Inverted urothelial papillomas with foamy or vacuolated cytoplasm. Hum Pathol 2006; 37: 1577–1582.
402. Ho H, Chen YD, Tan PH, et al. Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center’s experience. Urology 2006; 68: 333–336.
403. Sung MT, Eble JN, Wang M, et al. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol 2006; 19: 1289–1294.
404. Lott S, Wang M, Zhang S, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol 2009; 22: 627–632.
405. Hodges KB, Lopez-Beltran A, Maclennan GT, Montironi R, Cheng L. Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. Br J Urol Int 2011; 107: 532–537.
406. Picozzi S, Casellato S, Bozzini G, et al. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients. Urol Oncol 2013; 31: 1584–1590.
407. Holmang S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001; 165: 1124–1128.
408. Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. Br J Urol Int 2003; 92: 559–562.
409. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002; 167: 1634–1637.
410. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 2005; 13: 143–153.
411. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999; 353: 974–977.
412. Chen SS, Chen KK, Lin AT, et al. The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder. Br J Urol 1996; 78: 209–212.
413. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential: clinical and biological implications. Cancer 1999; 86: 2102–2108.
414. Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 WHO/ISUP classification of urothelial neoplasms – practical choices for patient care. J Urol 2002; 168: 968–972.
415. Paner GP, Zehnder P, Amin AM, Husain AN, Desai MM. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management. Adv Anat Pathol 2011; 18: 79–89.
416. Campbell PA, Conrad RJ, Campbell CM, Nicol DL, MacTaggart P. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome. BJU Int 2004; 93: 1228–1231.
417. Cheng L, Weaver AL, Leibovich BC. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 2000; 88: 2326–2332.
418. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, et al. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol 2002; 55: 900–905.
419. Mostofi FK, Davis CJ, Sesterhenn IA. Histological Typing of Urinary Bladder Tumours. International Histological Classification of Tumours. Berlin: Springer; 1999.
420. Murphy WM, Busch C, Algaba F. Intraepithelial lesions of urinary bladder: morphologic considerations. Scand J Urol Nephrol Suppl 2000; 67–81.
421. Smith G, Elton RA, Beynon LL, et al. Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br J Urol 1983; 55: 665–669.
422. Orozco RE, Martin AA, Murphy WM. Carcinoma in-situ of the urinary bladder: clues to host involvement in human carcinogenesis. Cancer 1994; 74: 115–122.
423. Orozco RE, Vander Zwaag R, Murphy WM. The pagetoid variant of urothelial carcinoma in situ. Hum Pathol 1993; 24: 1199–1202.
424. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium. Am J Surg Pathol 2001; 25: 1074–1078.
425. Gunia S, Koch S, Hakenberg OW, et al. Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa. Am J Clin Pathol 2011; 136: 881–888.
426. Nese N, Gupta R, Bui MH, Amin MB. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Cancer Netw 2009; 7: 48–57.
427. Varinot J, Camparo P, Roupret M, et al. Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage. Virchows Arch 2009; 455: 449–453.
428. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Therapeut Adv Urol 2012; 4: 13–32.
429. Jimenez RE, Keane TE, Hardy HT, Amin MB. pT1 urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol 2000; 7: 13–25.
430. Segal R, Yafi FA, Brimo F, et al. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2012; 109: 1026–1030.
431. Gondo T, Nakashima J, Ozu C, et al. Risk stratification of survival by lymphovascular invasion, pathological stage, and surgical margin in patients with bladder cancer treated with radical cystectomy. Int J Clin Oncol 2012; 17: 456–461.
432. Miocinovic R, Gong MC, Ghoneim IA, et al. Presacral and retroperitoneal lymph node involvement in urothelial bladder cancer: results of a prospective mapping study. J Urol 2011; 186: 1269–1273.
433. Turker P, Bostrom PJ, Wroclawski ML, et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int 2012; 110: 804–811.
434. Brunocilla E, Pernetti R, Martorana G. The prognostic role of lymphovascular invasion in urothelial-cell carcinoma of upper and lower urinary tract. Anticancer Res 2011; 31: 3503–3506.
435. May M, Bastian PJ, Brookman-May S, et al. External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladder. J Urol 2012; 187: 1210–1214.
436. Saito K, Kawakami S, Fujii Y, et al. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically. J Urol 2007; 178: 2291–2296.
437. Cho KS, Seo HK, Joung JY, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 2009; 182: 2625–2630.
438. Kunju LP, You L, Zhang Y, et al. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 2008; 180: 1928–1932.
439. Afonso J, Santos LL, Amaro T, Lobo F, Longatto-Filho A. The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion – the prognostic contribution of related molecular markers. Histopathology 2009; 55: 514–524.
440. Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Clinicopathological significance of lymphovascular invasion in urothelial carcinoma. Anal Quant Cytol Histol 2012; 34: 173–179.
441. Talbert ML, Young RH. Carcinomas of the urinary bladder with deceptively benign-appearing foci: a report of three cases. Am J Surg Pathol 1989; 13: 374–378.
442. Murphy WM, Deana DG. The nested variant of transitional cell carcinoma: a neoplasm resembling proliferation of Brunn’s nests. Mod Pathol 1992; 5: 240–243.
443. Cardillo M, Reuter VE, Lin O. Cytologic features of the nested variant of urothelial carcinoma: a study of seven cases. Cancer 2003; 99: 23–27.
444. Lin O, Cardillo M, Dalbagni G, et al. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases. Mod Pathol 2003; 16: 1289–1298.
445. Pusztaszeri M, Hauser J, Iselin C, Egger JF, Pelte MF. Urothelial carcinoma “nested variant” of renal pelvis and ureter. Urology 2007; 69: 778 e15–17.
446. Wasco MJ, Daignault S, Bradley D, Shah RB. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Hum Pathol 2010; 41: 163–171.
447. Amin MB, Ro JY, el-Sharkawy T, et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994; 18: 1224–1232.
448. Kamat AM, Dinney CP, Gee JR, et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007; 110: 62–67.
449. Compérat E, Roupret M, Yaxley J, et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology (Phila) 2010; 42: 650–654.
450. Sangoi AR, Beck AH, Amin MB, et al. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol 2010; 34: 1367–1376.
451. Ching CB, Amin MB, Tubbs RR, et al. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol 2011; 24: 1111–1119.
452. Cheng L, Davidson DD, Maclennan GT, et al. The origins of urothelial carcinoma. Exp Rev Anticancer Ther 2010; 10: 865–880.
453. Williamson SR, Zhang S, Lopez-Beltran A, et al. Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol 2011; 35: 474–483.
454. Amin MB, Ro JY, Lee KM, et al. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol 1994; 18: 466–473.
455. Cheng L, Davidson DD, Mclennan GT, et al. The origins of urothelial carcinoma. Expert Rev Anticancer Ther 2010; 10: 865–880.
456. Lopez-Beltran A, Luque RJ, Vicioso L, et al. Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. Virchows Arch 2001; 438: 552–557.
457. Baydar D, Amin MB, Epstein JI. Osteoclast-rich undifferentiated carcinomas of the urinary tract. Mod Pathol 2006; 19: 161–171.
458. Bui MM, Purohit CN, Hakam A. Fine needle aspiration biopsy of an osteoclast-rich undifferentiated urothelial carcinoma: a cytology case report and review of the literature. CytoJournal 2010; 7: 18.
459. Castelino-Prabhu S, Ali SZ. Osteoclast-rich undifferentiated carcinoma of the urinary tract: cytologic findings and literature review. Diagn Cytopathol 2010; 38: 364–367.
460. Lagwinski N, Thomas A, Stephenson AJ, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 2007; 31: 1777–1787.
461. Newman DM, Brown JR, Jay AC, Pontius EE. Squamous cell carcinoma of the bladder. J Urol 1968; 100: 470–473.
462. Rogers CG, Palapattu GS, Shariat SF, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006; 175: 2048–2053; discussion 2053.
463. Chan TY, Epstein JI. In situ adenocarcinoma of the bladder. Am J Surg Pathol 2001; 25: 892–899.
464. Miller JS, Epstein JI. Noninvasive urothelial carcinoma of the bladder with glandular differentiation: report of 24 cases. Am J Surg Pathol 2009; 33: 1241–1248.
465. Nigwekar P, Tamboli P, Amin MB, et al. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol 2009; 33: 417–424.
466. Ro JY, Shen SS, Lee HI, et al. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol 2008; 32: 752–757.
467. Thomas AA, Stephenson AJ, Campbell SC, Jones JS, Hansel DE. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol 2009; 40: 108–116.
468. Paz A, Rath-Wolfson L, Lask D, et al. The clinical and histological features of transitional cell carcinoma of the bladder with microcysts: analysis of 12 cases. Br J Urol 1997; 79: 722–725.
469. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005; 166: 1533–1539.
470. Jones TD, Kernek KM, Yang XJ, et al. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol 2005; 36: 718–723.
471. Pan CX, Yang XJ, Lopez-Beltran A, et al. c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol 2005; 18: 320–323.
472. Wang X, Zhang S, MacLennan GT, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 2007; 13: 953–957.
473. Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 2005; 46: 57–63.
474. Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol 2009; 27: 101–106.
475. Chen YB, Epstein JI. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. Am J Surg Pathol 2011; 35: 442–446.
476. Chin NW, Marinescu AM, Fani K. Composite adenocarcinoma and carcinoid tumor of urinary bladder. Urology 1992; 40: 249–452.
477. Stanfield BL, Grimes MM, Kay S. Primary carcinoid tumor of the bladder arising beneath an inverted papilloma. Arch Pathol Lab Med 1994; 118: 666–667.
478. Martignoni G, Eble JN. Carcinoid tumors of the urinary bladder. Immunohistochemical study of 2 cases and review of the literature. Arch Pathol Lab Med 2003; 127: e22–24.
479. Mazzucchelli R, Morichetti D, Lopez-Beltran A, et al. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. Br J Urol Int 2009; 103: 1464–1470.
480. Zozumi M, Nakai M, Matsuda I, et al. Primary carcinoid tumor of the urinary bladder with prominent subnuclear eosinophilic granules. Pathol Res Pract 2012; 208: 109–112.
481. Engles CD, Slobodov G, Buethe DD, Lightfoot S, Culkin DJ. Primary mixed neuroendocrine carcinoma of the bladder with large cell component: a case report and review of the literature. Int Urol Nephrol 2012; 44: 1021–1025.
482. Dundr P, Pesl M, Povýsil C, Vítková I, Dvorácek J. Large cell neuroendocrine carcinoma of the urinary bladder with lymphoepithelioma-like features. Pathol Res Pract 2003; 199: 559–563.
483. Evans AJ, Al-Maghrabi J, Tsihlias J, et al. Primary large cell neuroendocrine carcinoma of the urinary bladder. Arch Pathol Lab Med 2002; 126: 1229–1232.
484. Hailemariam S, Gaspert A, Komminoth P, Tamboli P, Amin M. Primary, pure, large-cell neuroendocrine carcinoma of the urinary bladder. Mod Pathol 1998; 11: 1016–1020.
485. Lee KH, Ryu SB, Lee MC, et al. Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int 2006; 56: 688–693.
486. Oshiro H, Gomi K, Nagahama K, et al. Urinary cytologic features of primary large cell neuroendocrine carcinoma of the urinary bladder: a case report. Acta Cytol 2010; 54: 303–310.
487. Xiao GQ, Chow J, Unger PD. Metastatic tumors to the urinary bladder: clinicopathologic study of 11 cases. Int J Surg Pathol 2012; 20: 342–348.
488. Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. Histopathology 2000; 36: 32–40.
489. Silver SA, Epstein JI. Adenocarcinoma of the colon simulating primary urinary bladder neoplasia. A report of nine cases. Am J Surg Pathol 1993; 17: 171–178.
490. Chia I, Grote D, Marcotte M, et al. Nephric duct insertion is a crucial step in urinary tract maturation that is regulated by a Gata3-Raldh2-Ret molecular network in mice. Development 2011; 138: 2089–2097.
491. Raspollini MR, Comin CE, Crisci A, Chilosi M. The use of placental S-100 (S-100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica 2010; 102: 33–35.
492. Raspollini MR, Sardi I, Giunti L, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. Hum Pathol 2011; 42: 1149–1158.
493. Suh N, Yang XJ, Tretiakova MS, Humphrey PA, Wang HL. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 2005; 18: 1217–1222.
494. Cesarani F, Garretti L, Denegri F, Valente G, Rossetti SR. Sonographic appearance of aggressive angiomyxoma of the bladder. J Clin Ultrasound 1999; 27: 399–401.
495. Cheng L, Scheithauer BW, Leibovich BC. Neurofibroma of the urinary bladder. Cancer 1999; 86: 505–513.
496. Corti B, Carella R, Gabusi E, et al. Solitary fibrous tumour of the urinary bladder with expression of bcl-2, CD34, and insulin-like growth factor type II. Eur Urol 2001; 39: 484–488.
497. Eggener SE, Hairston J, Rubenstein JN, Gonzalez CM. Bladder lipoma. J Urol 2001; 166: 1395.
498. Skopelitou A, Mitselou A, Gloustianou G. Xanthoma of the bladder associated with transitional cell carcinoma. J Urol 2000; 164: 1303–1304.
499. Wang W, Montgomery E, Epstein JI. Benign nerve sheath tumors on urinary bladder biopsy. Am J Surg Pathol 2008; 32: 907–912.
500. Ghalayini IF, Bani-Hani IH, Almasri NM. Osteosarcoma of the urinary bladder occurring simultaneously with prostate and bowel carcinomas: report of a case and review of the literature. Arch Pathol Lab Med 2001; 125: 793–795.
501. Navon JD, Rahimzadeh M, Wong AK, Carpenter PM, Ahlering TE. Angiosarcoma of the bladder after therapeutic irradiation for prostate cancer. J Urol 1997; 157: 1359–1360.
502. Tavora F, Montgomery E, Epstein JI. A series of vascular tumors and tumorlike lesions of the bladder. Am J Surg Pathol 2008; 32: 1213–1219.
503. Westra WH, Grenko RT, Epstein J. Solitary fibrous tumor of the lower urogenital tract: a report of five cases involving the seminal vesicles, urinary bladder, and prostate. Hum Pathol 2000; 31: 63–68.
504. Alanee S, Shukla AR. Bladder malignancies in children aged < 18 years: results from the Surveillance, Epidemiology and End Results database. BJU Int 2010; 106: 557–560.
505. Mondaini N, Palli D, Saieva C, et al. Clinical characteristics and overall survival in genitourinary sarcomas treated with curative intent: a multicenter study. Eur Urol 2005; 47: 468–473.
506. Bing Z, Zhang PJ. Adult urinary bladder tumors with rhabdomyosarcomatous differentiation: clinical, pathological and immunohistochemical studies. Diagn Pathol 2011; 15: 66.
507. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3–FKHR and PAX7–FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group. J Clin Oncol 2002; 20: 2672–2679.
508. Leuschner I, Harms D, Mattke A, Koscielniak E, Treuner J. Rhabdomyosarcoma of the urinary bladder and vagina: a clinicopathologic study with emphasis on recurrent disease: a report from the Kiel Pediatric Tumor Registry and the German CWS Study. Am J Surg Pathol 2001; 25: 856–864.
509. Paner GP, McKenney JK, Epstein JI, Amin MB. Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma. Am J Surg Pathol 2008; 32: 1022–1028.
510. Lee TK, Miyamoto H, Osunkoya AO, et al. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases. Am J Surg Pathol 2010; 34: 502–509.
511. Kunze E, Theuring F, Krüger G. Primary mesenchymal tumors of the urinary bladder. A histological and immunohistochemical study of 30 cases. Pathol Res Practice 1994; 190: 311–332.
512. Martin SA, Sears DL, Sebo TJ, Lohse CM, Cheville JC. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic comparison of leiomyoma and leiomyosarcoma. Am J Surg Pathol 2002; 26: 292–300.
513. Westfall DE, Folpe AL, Paner GP, et al. Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. Am J Surg Pathol 2009; 33: 99–105.
514. Yagnik V, Chadha A, Chaudhari S, Patel K. Inflammatory myofibroblastic tumor of the urinary bladder. Urol Ann 2010; 2: 78–79.
515. Sukov WR, Cheville JC, Carlson AW, et al. Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol 2007; 20: 592–603.
516. Montgomery EA, Shuster DD, Burkart AL, et al. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol 2006; 30: 1502–1512.
517. Coffin CM, Humphrey PA, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol 1998; 15: 85–101.
518. Hirsch MS, Dal Cin P, Fletcher CD. ALK expression in pseudosarcomatous myofibroblastic proliferations of the genitourinary tract. Histopathology 2006; 48: 569–578.
519. Tsuzuki T, Magi-Galluzzi C, Epstein JI. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol 2004; 28: 1609–1614.
520. Rao RN, Ranjan P, Singla N, Pandey R. Inflammatory myofibroblastic tumor of the urinary bladder diagnosed by anaplastic lymphoma kinase immunostaining. Urol Ann 2012; 4: 115–118.
521. Zhou M, Epstein JI, Young R. Paraganglioma of the urinary bladder: a lesion that may be misdiagnosed as urothelial carcinoma in transurethral resection specimens. Am J Surg Pathol 2004; 28: 94–100.
522. Edström E, Mahlamäki E, Nord B, et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol 2000; 156: 651–659.
523. Sandgren J, Diaz de Ståhl T, Andersson R, et al. Recurrent genomic alterations in benign and malignant pheochromocytomas and paragangliomas revealed by whole-genome array comparative genomic hybridization analysis. Endocrine Related Cancer 2010; 17: 561–579.
524. Vicha A, Holzerova M, Krepelova A, et al. Molecular cytogenetic characterization in four pediatric pheochromocytomas and paragangliomas. Pathol Oncol Res 2011; 27: 801–808.
525. Kempton CL, Kurtin PJ, Inwards DJ, Wollan P, Bostwick DG. Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. Am J Surg Pathol 1997; 21: 1324–1333.
526. Ho DS, Patterson AL, Orozco RE, Murphy WM. Extramedullary plasmacytoma of the bladder: case report and review of the literature. J Urol 1993; 150: 473–474.
527. Baker PM, Young RH. Radiation-induced pseudocarcinomatous proliferations of the urinary bladder: a report of 4 cases. Hum Pathol 2000; 31: 678–683.
528. Chan TY, Epstein JI. Radiation or chemotherapy cystitis with “pseudocarcinomatous” features. Am J Surg Pathol 2004; 28: 909–913.
529. Hameed O, Humphrey PA. Pseudoneoplastic mimics of prostate and bladder carcinomas. Arch Pathol Lab Med 2010; 134: 427–443.
530. Lane Z, Epstein JI. Pseudocarcinomatous epithelial hyperplasia in the bladder unassociated with prior irradiation or chemotherapy. Am J Surg Pathol 2008; 32: 92–97.
531. Eble JN. Examination of urinary bladder specimens. In Foster CSR, Ross J, eds. Pathology of the Urinary Bladder. Philadelphia, PA: Elsevier; 2004: pp. 191–197.
532. Scosyrev E, Yao J, Messing E. Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice. Urology 2010; 76: 908–913.
533. Zhang ZL, Xiong YH, Li YH, et al. Reassessment of the predictive role of perivesical fat invasion in invasive bladder cancer prognosis in 151 Chinese patients. Chin Med J (Engl) 2011; 124: 2915–2919.
534. Cullen TS. Embryology, Anatomy and Diseases of the Umbilicus together with Diseases of the Urachus. Philadelphia, PA: WB Saunders; 1916.
535. Hammond G, Yglesias L, Davis JE. The urachus: its anatomy and associated fasciae. Anat Rec 1941; 80: 271–287.
536. Vaughan GT. Patent urachus: review of the cases reported. Operation on a case complicated with stones in the kidneys. A note on tumors and cysts of the urachus. Trans Am Surg Assoc 1905; 23: 273–294.
537. Hinman FJ. Urologic aspects of the alternating urachal sinus. Am J Surg 1961; 102: 339–342.
538. Groff DB. Suprapubic dermoid sinus. J Pediatr Surg 1993; 28: 242–243.
539. Dreyfuss ML, Fleiss MM. Patent urachus with stone formation. J Urol 1941; 47: 77–81.
540. Nargund VH, Donaldson RA. Urachal calculi: a case report and review of the literature. Int Urol Nephrol 1994; 26: 409–411.
541. Blichert-Toft M, Koch F, Nielsen OV. Anatomic variants of the urachus related to clinical appearance and surgical treatment. Surg Gynecol Obstet 1973; 137: 51–54.
542. Schubert GE, Pavkovic MB, Bethke-Bedurftig BA. Tubular urachal remnants in adult bladders. J Urol 1982; 127: 40–42.
543. Wutz JB. Ueber Urachus und Urachuscysten. Virchows Arch Pathol Anat Physiol Klin Med 1883; 92: 387–423.
544. Tyler DE. Epithelium of intestinal type in the normal urachus: a new theory of vesical embryology. J Urol 1964; 92: 505–507.
545. Satake T, Takeda A, Matsuyama M. Argyrophil cells in the urachal epithelium and urachal adenocarcinoma. Acta Pathol Japon 1984; 34: 1193–1199.
546. Lattimer JK. Congenital deficiency of the abdominal musculature and associated genitourinary anomalies: a report of 22 cases. J Urol 1958; 79: 343–352.
547. Schreck WR, Campbell WA III. The relation of bladder outlet obstruction to urinary–umbilical fistula. J Urol 1972; 108: 641–643.
548. Iuchtman M, Rahav S, Zer M, Mogilner J, Siplovich L. Management of urachal anomalies in children and adults. Urology 1993; 42: 426–430.
549. Brodie N. Infected urachal cysts. Am J Surg 1945; 69: 243–248.
550. Lees VC, Doyle PT. Urachal cyst presenting with abscess formation. J R Soc Med 1991; 84: 367–368.
551. MacMillan RW, Schullinger JN, Santulli TV. Pyourachus: an unusual surgical problem. J Pediatr Surg 1973; 8: 387–389.
552. MacNeily AE, Kolleilat N, Kiruluta HG, Homsy YL. Urachal abscesses: protean manifestations, their recognition and management. Urology 1992; 40: 530–535.
553. Chen W-H, Hsieh H-H, Wan Y-L. Abscesss of urachal remnant mimicking urinary bladder neoplasm. Br J Urol 1992; 69: 510–512.
554. Micheli E, Hurle R, Losa A, et al. Primary actinomycosis of the urachus. Br J Urol Int 1999; 83: 144–145.
555. Nagy V, Sokol L, Ba-a M, et al. Actinomycosis of the urachus persistens penetrating into the ileum. Int Urol Nephrol 1997; 29: 627–631.
556. Thompson NP, Stoker DL, Springall RG. Urachal abscess as a complication of tinea corporis. Br J Urol 1994; 73: 319.
557. Carrere W, Gutierrez R, Umbert B, et al. Urachal xanthogranulomatous disease. Br J Urol 1996; 77: 612–613.
558. Hamm FC. Benign cystadenoma of the bladder, probably of urachal origin. J Urol 1940; 44: 227–233.
559. de Bree E, Witkamp A, Van de Vijver M, Zoetmulde F. Unusual origins of Pseudomyxoma peritonei. J Surg Oncol 2000; 75: 270–274.
560. de Korte WE. An adenoma of the bladder. J Pathol Bacteriol 1918; 22: 319–323.
561. Ng KJ, Newman P, Price-Thomas JM. Carcinoma of the urachus associated with urachal adenoma. Br J Urol 1991; 67: 215–216.
562. Cornil C, Reynolds CT, Kickham CJE. Carcinoma of the urachus. J Urol 1967; 98: 93–95.
563. Ohman U, von Garrelets B, Moberg A. Carcinoma of the urachus, review of the literature and report of two cases. Scand J Urol Nephrol 1971; 5: 91–95.
564. Petersen RO. Urologic Pathology. Philadelphia, PA: J.B. Lippincott Company; 1986.
565. Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J Urol 1984; 131: 1–8.
566. Ghazizadeh M, Yamamoto S, Kurokawa K. Clinical features of urachal carcinoma in Japan: review of 157 patients. Urol Res 1983; 11: 235–238.
567. Bennett JK, Trulock TS, Finnerty DP. Urachal adenocarcinoma presenting as vesicoenteric fistula. Urology 1985; 25: 297–299.
568. Hayman J Carcinoma of the urachus. Pathology (Phila) 1984; 16: 167–171.
569. Johnson DE, Hodge GB, Abdul-Karim FW, Ayala AG. Urachal carcinoma. Urology 1985; 26: 218–221.
570. Kakizoe T, Matsumoto K, Andoh M, Nishio Y, Kishi K. Adenocarcinoma of urachus, report of 7 cases and review of literature. Urology 1983; 21: 360–366.
571. Mattelaer P, Wolff JM, Jung P, Ijzerman W, Jakse G. Adenocarcinoma of the urachus: 3 case reports and a review of the literature. Acta Urol Belg 1997; 65: 63–67.
572. Michielsen D, Hoekx L, Dewilde L, Wyndaele JJ. Carcinoma of the urachus. Acta Urol Belg 1995; 63: 33–35.
573. Taylor GD, McRae CU. Carcinoma of the urachus: report of four cases and review of the literature. N Z Med J 1978; 87: 384–386.
574. Lurie A, Eisenkraft S, Shotland Y, Lurie M. Mucin-producing adenocarcinoma of the bladder of urachal origin, case report. Urol Int 1983; 38: 12–15.
575. Mostofi FK, Thomson RV, Dean AL.Mucous adenocarcinoma of the urinary bladder. Cancer 1955; 8: 741–758.
576. Abenoza P, Manivel C, Sibley RK. Adenocarcinoma with neuroendocrine differentiation of the urinary bladder, clinicopathologic, immunohistochemical and ultrastructural study. Arch Pathol Lab Med 1986; 110: 1062–1066.
577. Alonso-Gorrea M, Mompo-Sanchis JA, Jorda-Cuevas M, Froufe A, Jimenez Cruz JF. Signet ring cell adenocarcinoma of the urachus. Eur Urol 1985; 11: 282–284.
578. Begg RC. The colloid adenocarcinoma of the bladder vault arising from the epithelium of the urachal canal: with a critical survey of the tumours of the urachus. Br J Surg 1931; 18: 422–466.
579. Wheeler JD, Hill WT. Adenocarcinoma involving the urinary bladder. Cancer 1954; 7: 119–135.
580. Issa M, Feeley M, Kerin M, Tanner A, Keane F. Umbilical deposits from internal malignancy: Sister Mary Joseph’s nodule. Ir Med J 1987; 80: 152–153.
581. Hasegawa R, Fukushima S, Hirose M, et al. Histochemical demonstration of colonic type mucin in glandular metaplasia and adenocarcinoma of the human urinary bladder. Acta Pathol Japon 1987; 37: 1097–1103.
582. Tiltman AJ, Maytom PAN. Adenocarcinoma of the urinary bladder, histochemical distinction between urachal and metastatic carcinomas. S Afr Med J 1977; 51: 74–75.
583. Torenbeek R, Lagendijk JH, Van Diest PJ, et al. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology 1998; 32: 20–27.
584. Gopalan A, Sharp DS, Fine SW, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol 2009; 33: 659–668.
585. Nakanishi K, Kawai T, Suzuki M, Torikata C. Prognostic factors in urachal adenocarcinoma. A study in 41 specimens of DNA status, proliferating cell-nuclear antigen immunostaining, and argyrophilic nucleolar-organizer region counts. Hum Pathol 1996; 27: 240–247.
586. Upadhyay V, Kukkady A.Urachal remnants: an enigma. Eur J Pediatr Surg 2003; 13: 372–376.
587. Chen K, Workman RD, Rainwater G. Urachal signet-ring cell carcinoma. Urology 1990; 36: 339–340.
588. Daljeet S, Amreek S, Satish J, et al. Signet ring cell adenocarcinoma of the urachus. Int J Urol 2004; 11: 785–788.
589. Egevad L, Håkansson U, Grabe M, Ehrnstrom R. Urachal signet-cell adenocarcinoma. Scand J Urol Nephrol 2009; 43: 88–91.
590. Fiter L, Gimeno F, Martin L, Gómez Tejeda L. Signet-ring cell adenocarcinoma of bladder. Urology 1993; 41: 30–33
591. Grignon DJ, Ro JY, Ayala AG, Johnson DE. Primary signet-ring cell carcinoma of the urinary bladder. Am J Clin Pathol 1991; 95: 13–20.
592. Jakse G, Schneider H-M, Jacobi GH. Urachal signet-ring cell carcinoma, a rare variant of vesical adenocarcinoma: incidence and pathological criteria. J Urol 1978; 120: 764–766.
593. Kondo A, Ogisu B, Mitsuya H. Signet-ring cell carcinoma involving the urinary bladder. Report of a case and review of 21 cases. Urol Int 1981; 36: 373–379.
594. Loggie BW, Fleming RA, Hosseinian AA. Peritoneal carcinomatosis with urachal signet-cell adenocarcinoma. Urology 1997; 50: 446–448.
595. Morii A, Furuya Y, Fujiuchi Y, et al. Urachal signet ring cell carcinoma. Int J Urol 2007; 14: 360–361.
596. Ravi R. Signet-ring cell carcinoma of urachus: a case report and review of literature. Arch Esp Urol 1990; 43: 927–929.
597. Romics I, Székely E, Szendroi A. Signet-ring cell carcinoma arising from the urinary bladder. Can J Urol 2008; 15: 4266–4268.
598. Jimi A, Munaoka H, Sato S, Iwata Y. Squamous cell carcinoma of the urachus. A case report and review of literature. Acta Pathol Japon 1986; 36: 945–952.
599. Shaw RE. Squamous-cell carcinoma in a cyst of the urachus. Br J Urol 1958; 30: 87–89.
600. Lin RY, Rappoport AE, Deppisch LM, Natividad NS, Katz W. Squamous cell carcinoma of the urachus. J Urol 1977; 118: 1066–1067.
601. Pujari BD, Phansopkar M, Deodhare SG. Squamous cell carcinoma of the urachus with vesical calculus. Br J Urol 1977; 49: 292.
602. Fujiyama C, Nakashima N, Tokuda Y, Uozumi J. Squamous cell carcinoma of the urachus. Int J Urol 2007; 14: 966–968.
603. Kodali S, Ratnasabapathy C, Sivamurthy S. Metastatic squamous cell carcinoma of the urachus. Clin Adv Hematol Oncol 2007; 5: 887–889.
604. Kuramoto T, Kikkawa K, Nishihata M, et al. Squamous cell carcinoma of the urachus producing granulocyte colony-stimulating factor. Urology 2009; 73: 442.e5–7.
605. Davis BL, Robinson DG. Diverticula of the female urethra: assay of 120 cases. J Urol 1970; 104: 850–853.
606. Duckett JW, Snow BW. Disorders of the urethra and penis. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, eds. Campbell’s Urology, 5th edn. Philadelphia, PA: WB Saunders; 1986: pp. 2000–2030.
607. Gonzalez MO, Harrison ML, Boileau MA. Carcinoma in diverticulum of female urethra. Urology 1985; 26: 328–332.
608. Mostofi FK, Price EBJ. Tumors of the male genital system. In: Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 1973: pp. 263–266.
609. Walker AN, Mills SE. Papillary and polypoid tumors of the prostatic urethra. In: Damjanov I, Cohen AH, Mills SE, Young RH, eds. Progress in Reproductive and Urinary Tract Pathology. New York, NY: Field and Wood; 1989: pp. 113–137.
610. Halat S, Eble JN, Grignon DJ, et al. Ectopic prostatic tissue: histogenesis and histopathological characteristics. Histopathology 2011; 58: 750–758.
611. Kawaguchi S, Shigehara K, Sasagawa T, et al. A case study of human papillomavirus-associated bladder carcinoma developing after urethral condyloma acuminatum. Jpn J Clin Oncol 2012; 42: 455–458.
612. Grabstald H. Tumors of the urethra in men and women. Cancer 1973; 32: 1236–1255.
613. Hopkins SC, Nag SK, Soloway MS. Primary carcinoma of male urethra. Urology 1984; 23: 128–133.
614. Meis JM, Ayala AG, Johnson DE. Adenocarcinoma of the urethra in women: a clinicopathologic study. Cancer 1987; 60: 1038–1052.
615. Noel JC, Fayt I, Aguilar SF. Adenosquamous carcinoma arising in villous adenoma from female vulvar urethra. Acta Obstet Gynecol Scand 2006; 85: 373–376.
616. Cornella JL, Larson TR, Lee RA, Magrina JF, Kammerer-Doak D. Leiomyoma of the female urethra and bladder: report of twenty-three patients and review of the literature. Am J Obstet Gynecol 1997; 176: 1278–1285.
617. Joshi HB, Beck RO. Leiomyoma of the female urethra with upper tract dilation and treatment with transurethral resection: a case report and literature review. Tech Urol 2000; 6: 223–225.
618. Kanner WA, Drachenberg CB, Papadimitriou JC, et al. Urethral stromal tumor with pacemaker cell phenotype. Ultrastruct Pathol 2007; 31: 63–71.
619. Saad AG, Kaouk JH, Kaspar HG, Khauli RB. Leiomyoma of the urethra: report of 3 cases of a rare entity. Int J Surg Pathol 2003; 11: 123–126.
620. Daneshmand S. Adenomatous polyp of the verumontanum causing bladder outlet obstruction. Sci World J 2004; 4(Suppl 1): 89–91.
621. Dell’Atti C, Missere M, Restaino G, et al. Primary lymphoma of the female urethra. Rays 2005; 30: 269–272.
622. Ozel B, Ballard C. Urethral and paraurethral leiomyomas in the female patient. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 93–95.
623. Hardeman SW, Soloway MS. Urethral recurrence following radical cystectomy. J Urol 1990; 144: 666–669.
624. Hickey DP, Soloway MS, Murphy WM. Selective urethrectomy following cystoprostatectomy for bladder cancer. J Urol 1986; 136: 828–830.
625. Wolinska WH, Melamed MR, Schellhammer PF, Whitmore WFJ. Urethral cytology following cystectomy for bladder carcinoma. Am J Surg Pathol 1977; 1: 225–234.
626. Drew PA, Murphy WM, Civantos F, Speights VO. The histogenesis of clear cell adenocarcinoma of the lower urinary tract: case series and review of the literature. Hum Pathol 1996; 27: 248–252.
627. Oliva E, Young RH. Clear cell adenocarcinoma of the urethra: a clinicopathologic analysis of 19 cases. Mod Pathol 1996; 9: 513–520.
628. Maloney KE, Wiener JS, Walther PJ. Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. J Urol 1994; 151: 360–364.
629. Wiener JS, Walther PJ. A high association of oncogenic human papillomaviruses with carcinomas of the female urethra: polymerase chain reaction-based analysis of multiple histological types. J Urol 1994; 151: 49–53.
630. Baker LR, Mallinson WJ, Gregory MC, et al. Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol 1987; 60: 497–503.
631. Bennington JL, Beckwith JB (1975) Tumors of the kidney, renal pelvis, and ureter. In Atlas of tumor pathology, pp 243–336. Washington DC: Armed Forces Institute of Pathology
632. Rha S, Byun J, Jung S, et al. The renal sinus: pathologic spectrum and multimodality imaging approach. Radiographics 2004; 24(Suppl 1): S117–131.
633. Borza T, Shah R, Faerber G, Wolf J. Localized amyloidosis of the upper urinary tract: a case series of three patients managed with reconstructive surgery or surveillance. J Endourol 2010; 24: 641–644.
634. Lewis JA, Vieralves G, Landes RR, Powell LW. Malakoplakia of the renal pelvis, calyces and upper ureter: case report. J Urol 1961; 85: 243–245.
635. Sozer I. A rare localization of malakoplakia: renal pelvis. J Urol 1966; 95: 746–748.
636. Feldman S, Levy L, Prinz L. Malacoplakia of the bladder causing bilteral ureteral obstruction. J Urol 1980; 123: 588–589.
637. Halpern G, Kalies D, Factor S, Wein A. Malacoplakia causing bilateral ureteropelvic junction obstruction. Urology 1974; 3: 628–631.
638. Sanchez L, Sanchez S, Bailey J. Malacoplakia presenting with obstructive nephropathy with bilateral ureter involvement. Nat Rev Nephrol 2009; 5: 418–422.
639. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006; 367: 241–251.
640. Salamis N, Tsiambas E, Tsohataridis E. Pelvic confined idiopathic retroperitoneal fibrosis mimicking a large tumor. Adv Med Sci 2009; 54: 296–298.
641. Stecker J, Rawls H, Devine C, Devine P. Retroperitoneal fibrosis and ergot derivatives. J Urol 1974; 112: 32–32.
642. Jimenez-Jimenez F, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson’s disease treated with pergolide. Clin Neuropharmacol 1995; 18: 277–279.
643. Silberstein S Methysergide. Cephalalgia 1998; 18: 421–435.
644. Holt R, Barnett A, Bailey C. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab 2010; 12: 1048–1057.
645. O’Rourke R, Wong D, Fleming S, Walker D. Erdheim–Chester disease: a rare cause of acute renal failure. Australas Radiol 2007; 51: Cpec No.: B48–51.
646. Banerji J, Gopalakrishnan G, Sriram K, Manipadam M. Localised retroperitoneal amyloidosis mimicking retroperitoneal fibrosis: a rare cause of obstructive uropathy. Singapore Med J 2009; 50: e332–335.
647. Kojima Y, Lambert S, Steixner B, Laryngakis N, Casale P. Multiple metachronous fibroepithelial polyps in children. J Urol 2011; 185: 1053–1057.
648. Wang XM, Jia LQ, Wang Y, Wang N. Utilizing ultrasonography in the diagnosis of pediatric fibroepithelial polyps causing ureteropelvic junction obstruction. Pediatr Radiol 2012; 42: 1107–1111.
649. Williams T, Wagner B, Corse W, Vestevich J. Fibroepithelial polyps of the urinary tract. Abdom Imag 2002; 27: 217–221.
650. Kuvel M, Canguven O, Murtazaoglu M, Albayrak S. Distribution of Cajal like cells and innervation in intrinsic ureteropelvic junction obstruction. Arch Ital Uro Androl 2011; 83: 128–132.
651. Koleda P, Apoznanski W, Wozniak Z, et al. Changes in interstitial cell of Cajal-like cells density in congenital ureteropelvic junction obstruction. Int Urol Nephrol 2012; 44: 7–12.
652. Solari V, Piotrowska AP, Puri P. Altered expression of interstitial cells of Cajal in congenital ureteropelvic junction obstruction. J Urol 2003; 170: 2420–2422.
653. MacMahon HE. Hypertrophic infundibular stenosis of the calyces of the kidney. Hum Pathol 1974; 5: 363–364.
654. Pieretti-Vanmarcke R, Pieretti A, Pieretti RV. Megacalycosis: a rare condition. Pediatr Nephrol 2009; 24: 1077–1079.
655. Lucaya J, Enriquez G, Delgado R, Castellote A. Infundibulopelvic stenosis in children. Am J Roentgenol 1984; 142: 471–474.
656. Klein F, Smith M, Kasenetz I. Pelvic lipomatosis: 35-year experience. J Urol 1988; 139: 998–1001.
657. Sharma S, Nabi G, Seth A, Thulkar S, Ghai S. Pelvic lipomatosis presenting as uraemic encephalopathy. Int J Clin Pract 2001; 55: 149–150.
658. Farina L. Re: Pelvic lipomatosis associated with cystitis glandularis and adenocarcinoma of the bladder. J Urol 1992; 147: 1380.
659. Tong R, Larner T, Finlay M, Agarawal D, Costello A. Pelvic lipomatosis associated with proliferative cystitis occuring in two brothers. Urology 2002; 59: 602.
660. Chen K, Felix E, Flam M. Extraadrenal myelolipoma. Am J Clin Pathol 1982; 78: 386–389.
661. Oliva A, Duarte B, Hammadeh R, Ghosh L, Baker R. Myelolipoma and endocrine dysfunction. Surgery 1988; 103: 711–715.
662. Amin M, Tickoo S, Schultz D. Myelolipoma of the renal sinus. An unusual site for a rare extra-adrenal lesion. Arch Pathol Lab Med 1999; 123: 631–634.
663. Clark P, Farver C, Ulchaker J, Angermeier K. A rare case of an extra-adrenal myelolipoma arising in the renal sinus: a case report and review of the literature. Sci World J 2005; 28: 109–117.
664. Talwalker S, Shaheen S. Extra-adrenal myelolipoma in the renal hilum: a case report and review of the literature. Arch Pathol Lab Med 2006; 130: 1049–1052.
665. Greaves W, Khanna P, DeLellis R, Glasser L, Wang L. Renal sinus myelolipoma coexistent with renal pelvis papillary transitional cell carcinoma: a case report. Int J Surg Pathol 2010; 18: 437–439.
666. Chan I, Lam W, Wong K, Tam PK. Renal pelvis haematoma causing pelviureteric obstruction: a first case of Antopol–Goldman lesion in a neonate. J Paediatr Child Hlth 2010; 46: 361–362.
667. Eccher A, Brunelli M, Gobbo S, et al. Subepithelial pelvic hematoma (Antopol–Goldman lesion) simulating renal neoplasm: report of a case and review of the literature. Int J Surg Pathol 2009; 17: 264–267.
668. Sanchez Zalabardo D, De Pablo Cardenas A, Fuertes Zarate A, et al. Antopol–Goldman lesion: a rare clinical entity in the differential diagnosis of macroscopic hematuria. Arch Espanol Urol 2012; 65: 258–262.
669. Levitt S, Waisman J, de Kernion J. Subepithelial hematoma of the renal pelvis (Antopol–Goldman lesion): a case report and review of the literature. J Urol 1984; 131: 939–941.
670. Titton R, Gervais D, Hahn P, et al. Urine leaks and urinomas: diagnosis and image-guided intervention. Radiographics 2003; 23: 1133–1147.
671. Jou Y, Shen C, Cheng M, Lin C, Chen P. Bilateral ureteral complete obstruction with huge spontaneous urinoma formation in a patient with advanced bladder cancer. J Chin Med Assoc 2012; 75: 84–86.
672. Grabstald H, Whitmore WF, Melamed MR. Renal pelvic tumors. JAMA 1971; 218: 845–854.
673. Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000; 164: 1523–1525.
674. Hall MC, Womack S, Sagalowsky AI, et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998; 52: 594–601.
675. Balaji KC, McGuire M, Grotas J, Grimaldi G, Russo P. Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation. J Urol 1999; 162: 1603–1606.
676. Mahadevia PS, Karwa GL, Koss LG. Mapping of urothelium in carcinomas of the renal pelvis and ureter: a report of nine cases. Cancer 1983; 51: 890–897.
677. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Huguet-Perez J, Vicente-Rodriguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk factors. J Urol 2000; 164: 1183–1187.
678. Mensch L, Trainer T, Plante M. Cystic hamartoma of the renal pelvis: a rare pathologic entity. Mod Pathol 1999; 12: 417–421.
679. Yoshida S, Nakagomi K, Goto S, Ozawa T. Cystic hamartoma of the renal pelvis. Int J Urol 2004; 11: 653–656.
680. Parada D, Moreira O, Gledhill T, et al. Cellular pseudosarcomatous fibroepithelial stromal polyp of the renal pelvis. APMIS 2005; 113: 70–74.
681. Milojevic B, Djokic M, Sipetic-Grujicic S, et al. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma. Urol Oncol 2012; 31: 1615–1620.
682. Aarnio M, Säily M, Juhola M, et al. Uroepithelial and kidney carcinoma in Lynch syndrome. Fam Cancer 2012; 11: 395–401.
683. Rouprêt M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 2008; 54: 1226–1236.
684. Holmäng S, Johansson SL. Synchronous bilateral ureteral and renal pelvic carcinomas: incidence, etiology, treatment and outcome. Cancer 2004; 101: 741–747.
685. Olgac S, Mazumdar M, Dalbagni G, Dalbagni G, Reuter VE. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol 2004; 28: 1545–1552.
686. Chow WH, Lindblad P, Gridley G, et al. Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst 1997; 89: 1453–1457.
687. Zhang X, Zhu Z, Zhong S, Xu T, Shen Z. Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria. World J Urol 2013; 31: 155–160.
688. Chan-Smutko G. Genetic testing by cancer site: urinary tract. Cancer J 2012; 18: 343–349.
689. Talseth-Palmer BA, Wijnen JT, Brenne IS, et al. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int J Cancer 2013; 132: 1556–1164.
690. Bing Z, Li J, Master SR, et al. Fluorescence in situ hybridization study of chromosome abnormalities of upper urinary tract urothelial carcinoma in paraffin-embedded tissue. Am J Clin Pathol 2012; 138: 382–389.
691. Audenet F, Colin P, Yates DR, et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. Br J Urol Int 2012; 110: E583–589.
692. Milojevic B, Djokic M, Sipetic-Grujicic S, et al. Upper urinary tract transitional cell carcinoma: location is not correlated with prognosis. Br J Urol Int 2012; 109: 1037–1042.
693. Cosentino M, Palou J, Gaya JM, et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol 2013; 31: 141–145.
694. Cohen RJ, Stanley JC, Dawkins HJ. Lymphoepithelioma-like carcinoma of the renal pelvis. Pathology (Phila) 1999; 31: 434–435.
695. Wen SC, Shen JT, Jang MY, et al. Lymphoepithelioma-like carcinoma of ureter – a rare case report and review of the literature. Kaohsiung J Med Sci 2012; 28: 509–513.
696. Iwata J, Fletcher CD. Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases. Pathol Int 2000; 50: 7–14.
697. Lv C, Chen N, Zhu X, Zhang X, Zhong Z. Primary leiomyosarcoma of the ureter. Asian J Surg 2008; 31: 191–194.
698. Miettinen M. Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma. Arch Pathol Lab Med 1988; 112: 637–640.
699. Koss LG. The cellular and acellular components of the urinary tract. In: Diagnostic Cytology of the Urinary Tract with Histopathologic & Clinical Correlation. Philadelphia, PA: Lippincott-Raven; 1996: pp. 17–29.
700. Droese M, Voeth C. Cytologic features of seminal vesicle epithelium in aspiration biopsy smears of the prostate. Acta Cytol 1976; 20: 120–125.
701. Betz SA, See WA, Cohen MB. Granulomatous inflammation in bladder wash specimens after intravesical Bacillus Calmette–Guerin therapy for transitional cell carcinoma of the bladder. Am J Clin Pathol 1993; 99: 244–248.
702. Koss LG, Sherman AB, Eppich E. Image analysis and DNA content of urothelial cells infected with human polyomavirus. Anal Quant Cytol 1984; 6: 89–94.
703. Kahan AV, Coleman DV, Koss LG. Activation of human polyoma virus infection. Detection by cytologic techniques. Am J Clin Pathol 1980; 74: 326–332.
704. Wojcik EM, Miller MC, Wright BC, Veltri RW, O’Dowd GJ. Comparative analysis of DNA content in Polyoma Virus infected urothelial cells, urothelial dysplasis and transitional cell carcinoma. Analyt Quant Cytol Histol 1997; 19: 430–436.
705. Rubben H, Hering F, Dahm HH, Lutzeyer W. Value of exfoliative urinary cytology for differentiation between uric acid stones and tumors of upper urinary tract. Urology 1982; 22: 571–573.
706. Murphy WM, Soloway MS, Finebaum PJ. Pathological changes associated with topical chemotherapy for superficial bladder cancer. J Urol 1981; 126: 461–464.
707. Raab SS, Lenel JC, Cohen MB. Low grade transitional cell carcinoma of the bladder. Cytologic diagnosis by key features as identified by logistic regression analysis. Cancer 1994; 74: 1621–1626.
708. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990; 21: 886–896.
709. Hattori M, Nishimura Y, Toyonaga M, et al. Cytological significance of abnormal squamous cells in urinary cytology. Diagn Cytopathol 2012; 40: 798–803.
710. Guan H, Tatsas AD, Ali SZ. Signet ring cell carcinoma in urine cytology: cytomorphologic findings and differential diagnosis. Acta Cytol 2012; 56: 177–182.
711. Thiryayi SA, Rana DN. Urine cytopathology: challenges, pitfalls, and mimics. Diagn Cytopathol 2012; 40: 1019–1034.